Research programme: central nervous system infection therapeutics - Maxwell Biosciences
Latest Information Update: 22 Nov 2022
At a glance
- Originator Maxwell Biosciences
- Class Peptoids
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS infections
Most Recent Events
- 12 Oct 2022 Maxwell Biosciences has patent protection for central nervous system infection therapeutics in USA (Maxwell Biosciences website, October 2022)
- 07 Oct 2022 Early research in CNS infections in USA (Intrathecal) (Maxwell Biosciences pipeline, October 2022)